Helen Bright


Affiliation: GlaxoSmithKline Research and Development
Country: USA


  1. Bright H, Carroll A, Watts P, Fenton R. Development of a GB virus B marmoset model and its validation with a novel series of hepatitis C virus NS3 protease inhibitors. J Virol. 2004;78:2062-71 pubmed
    ..These studies provide the first demonstration of the in vivo efficacy of a small-molecule inhibitor for HCV in an animal model and illustrate the utility of GBV-B as a surrogate animal model system for HCV...